公开(公告)号：US20140294822A1

公开(公告)日：2014-10-02

申请号：US14194463

申请日：2014-02-28

Applicant: ARMAGEN TECHNOLOGIES, INC.

Inventor： William M. PARDRIDGE ,  Ruben J. BOADO

IPC: C12N9/16 ,  C07K16/28

CPC classification number: C07K16/2869 ,  A61K2039/505 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2319/01 ,  C12N9/16 ,  C12N9/2402 ,  C12N15/62 ,  C12Y301/06008

Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.

Abstract translation: 本文提供了用于治疗患有CNS中芳基硫酸酯酶A缺乏症的受试者的方法和组合物。 所述方法包括全身施用包含人胰岛素受体抗体和芳基硫酸酯酶A的双功能融合抗体。

公开(公告)号：US08846866B2

公开(公告)日：2014-09-30

申请号：US13708528

申请日：2012-12-07

Applicant: The Regents of the University of California

Inventor： Isaac S. Carrico ,  Brian L. Carlson ,  Peng Wu ,  Carolyn Bertozzi

IPC: C07K1/00 ,  C07K16/00 ,  A61L33/00 ,  C07K1/13 ,  C07K1/107 ,  C07K14/00 ,  C12P21/00 ,  C07K16/46 ,  C12N9/96

CPC classification number: C07K16/00 ,  A61K38/1825 ,  A61K38/215 ,  A61K38/37 ,  A61K38/45 ,  A61K39/00 ,  C07K1/006 ,  C07K1/1072 ,  C07K1/13 ,  C07K14/00 ,  C07K14/35 ,  C07K14/565 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/622 ,  C12N9/13 ,  C12N9/96 ,  C12P21/00 ,  C12P21/005 ,  C12Y208/02

Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.

公开(公告)号：US08614308B2

公开(公告)日：2013-12-24

申请号：US13617248

申请日：2012-09-14

Applicant: John E. Park ,  Cornelia Dorner-Ciossek ,  Stefan Hoerer ,  Lothar Kussmaul ,  Martin Lenter ,  Katharina Zimmermann ,  Gerald Beste ,  Toon Laeremans ,  Pascal Merchiers ,  Jo Vercammen

Inventor： John E. Park ,  Cornelia Dorner-Ciossek ,  Stefan Hoerer ,  Lothar Kussmaul ,  Martin Lenter ,  Katharina Zimmermann ,  Gerald Beste ,  Toon Laeremans ,  Pascal Merchiers ,  Jo Vercammen

IPC: C12N15/13 ,  C12N5/07 ,  C12N5/16 ,  C12N1/00 ,  C07H21/00

CPC classification number: A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

Abstract translation: 本发明涉及双互补位A-β结合多肽，更具体地涉及包含结合至A-β的不同表位的至少两个免疫球蛋白单可变结构域的双互补位A-β结合多肽。 本发明还涉及这种多肽的具体序列，其生产方法及其使用方法，包括治疗疾病如阿尔茨海默病的方法。

公开(公告)号：US20130295102A1

公开(公告)日：2013-11-07

申请号：US13716526

申请日：2012-12-17

Applicant: Novartis AG

Inventor： Leslie Ngozi Anuna Johnson ,  Ute Jaeger ,  Yong-In Kim ,  Christian Carsten Silvester Kunz ,  Igor Splawski ,  Michael Roguska ,  Joy Ghosh ,  Barbara Brannetti

IPC: C07K16/18 ,  G01N33/68 ,  C07K16/24 ,  A61K39/395

CPC classification number: C07K16/18 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/24 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6863

Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind to complement Factor P and used thereof as well as combinations of anti-Factor P antibodies with antibodies or antigen binding fragments thereof that bind to complement component 5 (C5).

公开(公告)号：US20130287773A1

公开(公告)日：2013-10-31

申请号：US13862250

申请日：2013-04-12

Applicant: ArmaGen Technologies, Inc.

Inventor： William M. PARDRIDGE ,  Ruben J. BOADO

IPC: C12N9/16 ,  C07K16/28

CPC classification number: C07K16/2869 ,  A61K2039/505 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2319/01 ,  C12N9/16 ,  C12N9/2402 ,  C12N15/62 ,  C12Y301/06008

Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.

公开(公告)号：US20130280243A1

公开(公告)日：2013-10-24

申请号：US13660889

申请日：2012-10-25

Applicant: Roche Glycart AG

Inventor： FRANK HERTING ,  CHRISTIAN KLEIN

IPC: A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  A61K31/436

CPC classification number: A61K39/3955 ,  A61K31/436 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61N5/10 ,  C07K14/70596 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/41 ,  A61K2300/00

Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.

公开(公告)号：US08486399B2

公开(公告)日：2013-07-16

申请号：US13609099

申请日：2012-09-10

Applicant: William M. Pardridge ,  Ruben J. Boado

Inventor： William M. Pardridge ,  Ruben J. Boado

IPC: A61K38/43 ,  C12N9/00

CPC classification number: C07K16/2869 ,  A61K2039/505 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2319/01 ,  C12N9/16 ,  C12N9/2402 ,  C12N15/62 ,  C12Y301/06008

Abstract: Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A.

Abstract translation: 本文提供了用于治疗患有CNS中芳基硫酸酯酶A缺乏症的受试者的方法和组合物。 所述方法包括全身施用包含人胰岛素受体抗体和芳基硫酸酯酶A的双功能融合抗体。

公开(公告)号：US20130045219A1

公开(公告)日：2013-02-21

申请号：US13656922

申请日：2012-10-22

Applicant: UCB Pharma S.A. ,  Biogen Idec MA Inc.

Inventor： LINDA C. BURKLY ,  JANINE L. FERRANT-ORGETTAS ,  ELLEN A. GARBER ,  YEN-MING HSU ,  LIHE SU ,  FREDERICK R. TAYLOR ,  RALPH ADAMS ,  DEREK THOMAS BROWN ,  ANDREW GEORGE POPPLEWELL ,  MARTYN KIM ROBINSON ,  ANTHONY SHOCK ,  KERRY LOUISE TYSON

IPC: C07K16/28 ,  C12N15/63 ,  C12N1/21 ,  C12N1/15 ,  C12N1/19 ,  C12N5/10 ,  C12P21/00 ,  A61K39/395 ,  A61P29/00 ,  A61P37/06 ,  A61P19/02 ,  A61P19/04 ,  A61P1/00 ,  A61P17/06 ,  A61P25/00 ,  C12N15/12

CPC classification number: C07K16/2875 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.

Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不期望的免疫应答的疾病。

公开(公告)号：US08337845B2

公开(公告)日：2012-12-25

申请号：US13038471

申请日：2011-03-02

Applicant: John E. Park ,  Cornelia Dorner-Ciossek ,  Stefan Hoerer ,  Lothar Kussmaul ,  Martin Lenter ,  Katharina Zimmermann ,  Gerald Beste ,  Toon Laeremans ,  Pascal Merchiers ,  Jo Vercammen

Inventor： John E. Park ,  Cornelia Dorner-Ciossek ,  Stefan Hoerer ,  Lothar Kussmaul ,  Martin Lenter ,  Katharina Zimmermann ,  Gerald Beste ,  Toon Laeremans ,  Pascal Merchiers ,  Jo Vercammen

IPC: A61K39/395 ,  C07K16/18

CPC classification number: A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00

Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

Abstract translation: 本发明涉及双互补位A-β结合多肽，更具体地涉及包含结合至A-β的不同表位的至少两个免疫球蛋白单可变结构域的双互补位A-β结合多肽。 本发明还涉及这种多肽的具体序列，其生产方法及其使用方法，包括治疗疾病如阿尔茨海默病的方法。

公开(公告)号：US20120141460A1

公开(公告)日：2012-06-07

申请号：US13382561

申请日：2010-07-09

Applicant: Hilde Stals ,  Veronique De Brabandere ,  Peter Schotte

Inventor： Hilde Stals ,  Veronique De Brabandere ,  Peter Schotte

IPC: A61K39/395 ,  C07K16/00 ,  C12N15/13 ,  C07K17/08 ,  C12N1/21 ,  C12N5/10 ,  C12N1/19 ,  C07K17/00 ,  C12P21/02 ,  C12N15/63

CPC classification number: C07K16/00 ,  A61K47/60 ,  A61K47/65 ,  C07K2317/40 ,  C07K2317/569 ,  C07K2319/00

Abstract: The present invention provides methods for the expression and/or production of variable domains with a C-terminal extension that can be used for coupling of the variable domain to one or more further groups, residues or moieties. In the method of the invention a yield of at least 80% of variable domains with a cysteine containing C-terminal extension is obtained. Also variable domains are provided and polypeptides comprising one or more variable domains obtainable by the methods of the present invention, as well as compounds that comprise such variable domains and/or polypeptides coupled to one or more groups, residues or moieties.

Abstract translation: 本发明提供用于表达和/或产生具有C末端延伸的可变结构域的方法，其可用于将可变结构域偶联至一个或多个另外的基团，残基或部分。 在本发明的方法中，获得含有C末端延伸的半胱氨酸的至少80％的可变结构域的产率。 还提供了可变结构域，以及包含通过本发明的方法可获得的一个或多个可变结构域的多肽，以及包含与一个或多个基团，残基或部分偶联的可变结构域和/或多肽的化合物。